Harada M - Search Results

1

In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.

Ichikura H, Eto M, Ueno H, Harada M, Takayama K, Tokuda N, Tatsugami K, Naito S. Ichikura H, et al. Among authors: harada m. Oncol Rep. 2006 May;15(5):1333-7. Oncol Rep. 2006. PMID: 16596207

2

HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients.

Ishihara Y, Harada M, Azuma K, Tamura M, Shomura H, Fujii T, Itoh K, Shichijo S. Ishihara Y, et al. Among authors: harada m. Int J Oncol. 2004 Apr;24(4):967-75. Int J Oncol. 2004. PMID: 15010837

3

Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Harada M, et al. Oncol Rep. 2004 Sep;12(3):601-7. Oncol Rep. 2004. PMID: 15289844

4

Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma.

Eto M, Harada M, Tatsugami K, Harano M, Koga H, Matsuzaki G, Naito S. Eto M, et al. Among authors: harada m. BJU Int. 2005 Feb;95(3):421-4. doi: 10.1111/j.1464-410X.2005.05313.x. BJU Int. 2005. PMID: 15679807

5

Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.

Hara M, Matsueda S, Tamura M, Takedatsu H, Tanaka M, Kawano K, Mochizuki K, Kamura T, Itoh K, Harada M. Hara M, et al. Among authors: harada m. Int J Oncol. 2005 Nov;27(5):1371-9. Int J Oncol. 2005. PMID: 16211234

6

Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients.

Wang Y, Harada M, Yano H, Ogasawara S, Tanaka M, Yamada A, Itoh K. Wang Y, et al. Among authors: harada m. Oncol Rep. 2006 Feb;15(2):317-21. Oncol Rep. 2006. PMID: 16391848

7

Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.

Homma S, Harada M, Yano H, Ogasawara S, Shichijo S, Matsueda S, Komatsu N, Shomura H, Maeda Y, Sato Y, Todo S, Itoh K. Homma S, et al. Among authors: harada m. Int J Oncol. 2006 Sep;29(3):577-87. Int J Oncol. 2006. PMID: 16865273

8

Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.

Harada M, Ishihara Y, Itoh K, Yamanaka R. Harada M, et al. Oncol Rep. 2007 Mar;17(3):629-36. Oncol Rep. 2007. PMID: 17273744

9

Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease.

Eto M, Harano M, Tatsugami K, Harada M, Kamiryo Y, Kiyoshima K, Hamaguchi M, Tsuneyoshi M, Yoshikai Y, Naito S. Eto M, et al. Among authors: harada m. Clin Cancer Res. 2007 Feb 1;13(3):1029-35. doi: 10.1158/1078-0432.CCR-06-1578. Clin Cancer Res. 2007. PMID: 17289899

10

Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer.

Homma S, Komohara Y, Harada M, Saya H, Todo S, Itoh K, Noguchi M. Homma S, et al. Among authors: harada m. Oncol Rep. 2007 Aug;18(2):343-6. Oncol Rep. 2007. PMID: 17611654

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,939 results

Search Page

Filters